ERBB2 and ovarian carcinoma: This threshold, observed clinically in the ovarian cancer study as the level below which the HR favored seribantumab (HR<1.0), closely matched results from model simulations predicting seribantumab potency decreases when HER2 levels rise above ~200,000 receptors/cell.